Insulin-sensitizing Agents for Infertility Treatment in Woman with Polycystic Ovary Syndrome: a Narrative Review of Current Clinical Practice

Overview

Journal Hormones (Athens)

Specialty Endocrinology

Date 2023 Oct 4

PMID 37792213

Authors

Radmila Sparic

Mladen Andjic

Aleksandar Rakic

Jelica Bjekic-Macut

Sarantis Livadas

Olivera Kontic-Vucinic

George Mastorakos

Djuro Macut

Affiliations

Soon will be listed here.

Abstract

Purpose: Polycystic ovary syndrome (PCOS) is an endocrine, metabolic, and reproductive disorder which, according to the Rotterdam criteria, affects up to 24% of women of childbearing age. Although the prevalence of infertility in this subpopulation of women is high, the optimal treatment has not been fully established yet. Insulin resistance is considered to be an important mechanism involved in the development of PCOS; hence, the aim of this narrative review is to present an overview of the current pharmacological insulin-sensitizing treatment modalities for infertile women with PCOS.

Methods: A MEDLINE and PubMed search for the years 1990-2023 was performed using a combination of keywords. Clinical trials with insulin sensitizers used for infertility treatment as well as analyses of systematic reviews and meta-analyses were evaluated. When deemed necessary, additional articles referenced in the retrieved papers were included in this narrative review.

Results: Several insulin-sensitizing compounds and various therapeutical protocols are available for infertility treatment of women with PCOS. Metformin is the most common adjuvant medication to induce ovulation in infertile women with PCOS and is more frequently administered in combination with clomiphene citrate than on its own. Recently, inositol and glucagon-like peptide-1 (GLP-1) receptor agonists have emerged as possible options for infertility treatment in PCOS.

Conclusion: The future of medical treatment of PCOS women with infertility lies in a personalized pharmacological approach, which involves various compounds with different mechanisms of action that could modify ovarian function and endometrial receptivity, ultimately leading to better overall reproductive outcomes in these women.

Citing Articles

Genetics of primary hyperparathyroidism, our first Batrinos' scholar review, metabolic syndrome, and quite a bit of reproductive endocrinology: a great issue.

Stratakis C Hormones (Athens). 2024; 23(1):1-2.

PMID: 38195949 DOI: 10.1007/s42000-023-00523-w.

References

Conway G, Dewailly D, Diamanti-Kandarakis E, Escobar-Morreale H, Franks S, Gambineri A . The polycystic ovary syndrome: a position statement from the European Society of Endocrinology. Eur J Endocrinol. 2014; 171(4):P1-29. DOI: 10.1530/EJE-14-0253. View

Stevanovic D, Bozic-Antic I, Stanojlovic O, Vojnovic Milutinovic D, Bjekic-Macut J, Jancic J . Health-related quality of life questionnaire for polycystic ovary syndrome (PCOSQ-50): a psychometric study with the Serbian version. Women Health. 2019; 59(9):1015-1025. DOI: 10.1080/03630242.2019.1587664. View

Patel S . Polycystic ovary syndrome (PCOS), an inflammatory, systemic, lifestyle endocrinopathy. J Steroid Biochem Mol Biol. 2018; 182:27-36. DOI: 10.1016/j.jsbmb.2018.04.008. View

Panidis D, Tziomalos K, Misichronis G, Papadakis E, Betsas G, Katsikis I . Insulin resistance and endocrine characteristics of the different phenotypes of polycystic ovary syndrome: a prospective study. Hum Reprod. 2011; 27(2):541-9. DOI: 10.1093/humrep/der418. View

Macut D, Tziomalos K, Bozic-Antic I, Bjekic-Macut J, Katsikis I, Papadakis E . Non-alcoholic fatty liver disease is associated with insulin resistance and lipid accumulation product in women with polycystic ovary syndrome. Hum Reprod. 2016; 31(6):1347-53. DOI: 10.1093/humrep/dew076. View

Macut D, Bjekic-Macut J, Rahelic D, Doknic M . Insulin and the polycystic ovary syndrome. Diabetes Res Clin Pract. 2017; 130:163-170. DOI: 10.1016/j.diabres.2017.06.011. View

Homburg R . Management of infertility and prevention of ovarian hyperstimulation in women with polycystic ovary syndrome. Best Pract Res Clin Obstet Gynaecol. 2004; 18(5):773-88. DOI: 10.1016/j.bpobgyn.2004.05.006. View

Balen A, Rutherford A . Managing anovulatory infertility and polycystic ovary syndrome. BMJ. 2007; 335(7621):663-6. PMC: 1995495. DOI: 10.1136/bmj.39335.462303.80. View

Gadalla M, Norman R, Tay C, Hiam D, Melder A, Pundir J . Medical and Surgical Treatment of Reproductive Outcomes in Polycystic Ovary Syndrome: An Overview of Systematic Reviews. Int J Fertil Steril. 2019; 13(4):257-270. PMC: 6875858. DOI: 10.22074/ijfs.2020.5608. View

10.

Diamanti-Kandarakis E . Reproductive endocrinology: Infertility treatment in PCOS--is metformin in from the cold?. Nat Rev Endocrinol. 2012; 8(6):328-30. DOI: 10.1038/nrendo.2012.69. View

11.

Tsiami A, Goulis D, Sotiriadis A, Kolibianakis E . Higher ovulation rate with letrozole as compared with clomiphene citrate in infertile women with polycystic ovary syndrome: a systematic review and meta-analysis. Hormones (Athens). 2021; 20(3):449-461. DOI: 10.1007/s42000-021-00289-z. View

12.

Fleming R . The use of insulin sensitising agents in ovulation induction in women with polycystic ovary syndrome. Hormones (Athens). 2006; 5(3):171-8. DOI: 10.14310/horm.2002.11181. View

13.

Dunaif A, Thomas A . Current concepts in the polycystic ovary syndrome. Annu Rev Med. 2001; 52:401-19. DOI: 10.1146/annurev.med.52.1.401. View

14.

Kim J, Tfayli H, Michaliszyn S, Arslanian S . Impaired Lipolysis, Diminished Fat Oxidation, and Metabolic Inflexibility in Obese Girls With Polycystic Ovary Syndrome. J Clin Endocrinol Metab. 2017; 103(2):546-554. PMC: 5800835. DOI: 10.1210/jc.2017-01958. View

15.

Rudnicka E, Suchta K, Grymowicz M, Calik-Ksepka A, Smolarczyk K, Duszewska A . Chronic Low Grade Inflammation in Pathogenesis of PCOS. Int J Mol Sci. 2021; 22(7). PMC: 8038770. DOI: 10.3390/ijms22073789. View

16.

Vatier C, Christin-Maitre S, Vigouroux C . Role of insulin resistance on fertility - Focus on polycystic ovary syndrome. Ann Endocrinol (Paris). 2022; 83(3):199-202. DOI: 10.1016/j.ando.2022.04.004. View

17.

Liu Y, Li J, Yan Z, Liu D, Ma J, Tong N . Improvement of Insulin Sensitivity Increases Pregnancy Rate in Infertile PCOS Women: A Systemic Review. Front Endocrinol (Lausanne). 2021; 12:657889. PMC: 8042389. DOI: 10.3389/fendo.2021.657889. View

18.

Dunaif A, Segal K, Shelley D, Green G, Dobrjansky A, Licholai T . Evidence for distinctive and intrinsic defects in insulin action in polycystic ovary syndrome. Diabetes. 1992; 41(10):1257-66. DOI: 10.2337/diab.41.10.1257. View

19.

Petersen M, Shulman G . Mechanisms of Insulin Action and Insulin Resistance. Physiol Rev. 2018; 98(4):2133-2223. PMC: 6170977. DOI: 10.1152/physrev.00063.2017. View

20.

Diamanti-Kandarakis E, Papavassiliou A . Molecular mechanisms of insulin resistance in polycystic ovary syndrome. Trends Mol Med. 2006; 12(7):324-32. DOI: 10.1016/j.molmed.2006.05.006. View